CD72 negatively regulates KIT-mediated responses in human mast cells

Area of Science:

• Immunology
• Cell Biology
• Molecular Medicine

Background:

• KIT signaling is essential for mast cell function but dysregulated in mastocytosis.
• Activating KIT mutations drive abnormal mast cell growth and disease.
• Mast cell inhibitory receptors offer a potential therapeutic target.

Purpose of the Study:

• To investigate the expression and function of CD72 in human mast cells.
• To determine if CD72 activation can inhibit KIT-mediated mast cell responses.
• To explore CD72 as a therapeutic target for mast cell disorders.

Main Methods:

• Human mast cells were analyzed for CD72 expression.
• CD72 was ligated using an agonistic antibody (BU40) and its ligand (rCD100).
• KIT signaling pathways, including Src family kinases and ERK1/2, were assessed.
• Mast cell proliferation, chemotaxis, and chemokine production were measured.
• The effect on HMC1.2 human mast cell line growth was evaluated.

Main Results:

• CD72 is expressed on human mast cells.
• CD72 ligation led to its phosphorylation and association with SHP-1.
• This inhibited KIT-induced phosphorylation of Src kinases and ERK1/2.
• KIT-mediated mast cell proliferation, chemotaxis, and chemokine production were significantly reduced.
• BU40 and rCD100 downregulated HMC1.2 cell growth.

Conclusions:

• CD72 is expressed in human mast cells and functions as an inhibitory receptor.
• CD72 activation suppresses KIT signaling pathways.
• Targeting CD72 presents a novel therapeutic strategy for mastocytosis and other mast cell-related diseases.